Poolbeg Pharma获得了欧盟对其实验性流感药物的专利权,提高了其库存的9%。 Poolbeg Pharma gained EU patent for its experimental flu drug, boosting its stock 9%.

Poolbeg Pharma PLC为其实验药物POLB 001获得欧洲专利,该专利抑制了P38 MAP脂酶,以减少严重流感中的危险发炎,并可能治疗细胞释放综合症。 Poolbeg Pharma PLC secured a European patent for its experimental drug POLB 001, which inhibits the p38 MAP kinase enzyme to reduce dangerous inflammation in severe influenza and potentially treat cytokine release syndrome. 欧洲专利局授予的专利加强了该公司的知识产权,并支持其发展免疫调节疗法。 The patent, granted by the European Patent Office, strengthens the company’s intellectual property and supports its development of immune-modulating therapies. 新闻提升了投资者的信心, 将公司股份提升9%至4. The news boosted investor confidence, lifting the company’s shares 9% to 4.01p.